Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antigen binding proteins

a technology of binding proteins and antigens, applied in the field of antigen binding proteins, can solve the problems of difficult separation from the desired heterodimer monobodies, formation of undesired homodimers,

Active Publication Date: 2018-11-01
F HOFFMANN LA ROCHE INC
View PDF4 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention provides antigen binding proteins that have excellent biological or pharmacological activities, such as enhanced ADCC. These proteins can be used to treat diseases like cancer. Additionally, they have highly valuable pharmacokinetic properties, such as AUC0-inf、Cmax orC0.

Problems solved by technology

However during expression a considerably amount of undesired homodimer is formed as by-product, which is difficult to separate from the desired heterodimeric monobodies, as the homodimer and the heterodimer have the same or similar molecular weights.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antigen binding proteins
  • Antigen binding proteins
  • Antigen binding proteins

Examples

Experimental program
Comparison scheme
Effect test

example 1

Generation of MoAb-Dimer Antigen Binding Proteins

[0276]We designed antigen binding proteins according to the invention against c-Met (SEQ ID NO:1 and SEQ ID NO:2), IGF-1R (SEQ ID NO:3 and SEQ ID NO:4) and HER3 (SEQ ID NO:5 and SEQ ID NO:6) based on the design principle as shown in FIG. 1A. The respective constructs were transiently expressed in HEK293 cells as described above, and subsequently purified via Protein A affinity chromatography followed by size exclusion. FIGS. 2-4 depict the chromatograms of the size exclusion chromatography of the three different productions of antigen binding proteins as well as the corresponding SDS-PAGE under non-reducing and reducing conditions. In addition to peak 3 in FIG. 2, peak 2 in FIG. 3, peak 3 in FIG. 4 proteins eluting at earlier timepoints from the column peak 2 in FIG. 2, peak 1 in FIG. 3, peak 4 in FIG. 7 were observed. Based on their retention time it was calculated that they exhibited the double the molecular weight of the monovalent...

example 2

IGF-1R Binding Affinity

[0280]IGF-1R extracellular domain binding of the IGF1R AK18 MoAb-Dimer (“CH3-wt”) was compared to the binding of the parental IgG1 antibody by surface Plasmon resonance (SPR). FIG. 5 depicts the scheme of the SPR assay to determine the affinity. The analysis (double determination) showed that the IGF-1R binding affinity is retained in the IGF1R AK18 MoAb-Dimer (“CH3-wt”).

k(on)k(off)KDMab (IGF-1R)1.74E+06 6.63E−03 3.80E−09MoAb-Dimer (IGF-1R)1.5E+063.0E−032.01E−09(1. deter.)MoAb-Dimer (IGF-1R)1.5E+063.0E−032.05E−09(2. deter.)

example 3

Cellular Binding to IGF-1R Expressing Cell Lines

[0281]Cellular binding of IGF-1R MoAb-Dimer was demonstrated on A549 cells. A549 cells in the logarithmic growth phase were detached with accutase (Sigma) and 2×10e5 cells were used for each individual antibody incubation. IGF-1R antibody and MoAb-Dimer were added in a threefold dilution series (100-0.0003 μg / mL). Bound antibodies were visualized with a secondary Alexa488-coupled antibody (5 μg / mL) binding to the constant region of human immunoglobulin. Dead cells were stained with 7-AAD (BD) and excluded from the analysis. Fluorescence intensity of single cells was measured on a FACS Canto (BD Biosciences) flow cytometer. The data show that the MoAb-Dimer showed very similar halfmaximal binding to cells comparable to the parental IGF-1R IgG1 antibody. This implies that the MoAb-Dimer can bind with two arms to IGF-1R on cells and exhibits an avidity effect. However, the total mfi (mean fluorescence intensity) is higher for the MoAb-Dim...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to antigen binding proteins comprising two Fc parts, methods for their production, pharmaceutical compositions containing said antigen binding proteins, and uses thereof.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]The present application is a divisional of U.S. patent application Ser. No. 13 / 406,411, filed on Feb. 27, 2012, which claims priority under 35 USC § 119(a) to European patent application number EP 11156320.1, filed 28 Feb. 2011, the contents of which are incorporated herein by reference.SEQUENCE LISTING[0002]The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 146392015610SEQLIST.TXT, date recorded: Jul. 23, 2018, size: 33 KB).TECHNICAL FIELD[0003]The present invention relates to antigen binding proteins comprising two Fc parts, methods for their production, pharmaceutical compositions containing said antigen binding proteins, and uses thereof.BACKGROUND OF THE INVENTION[0004]In the last two decades various engineered antibody derivatives, either mono or- multispecific, either mono- or multivalent have been develop...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/00C07K16/28C07K16/32
CPCC07K16/2863C07K2317/94C07K2317/66C07K2317/76C07K16/00C07K2317/64C07K2317/41C07K2317/732C07K16/32C07K2317/77C07K2317/92A61P35/00G01N21/553C07K16/18A61K39/395C07K16/468C07K2317/72C12N15/85
Inventor BOSSENMAIER, BIRGITKETTENBERGER, HUBERTKLEIN, CHRISTIANKUENKELE, KLAUS-PETERREGULA, JOERG-THOMASSCHAEFER, WOLFGANGSCHWAIGER, MANFREDSUSTMANN, CLAUDIO
Owner F HOFFMANN LA ROCHE INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com